Evidence map›Paper›PMID 39320009›Full record

ArticleInfluenza and other respiratory viruses2024

Influenza Epidemiology and Vaccine Effectiveness Following Funded Influenza Vaccine in Queensland, Australia, 2022.

Ashish C Shrestha, Emma Field, Dharshi Thangarajah, Ross Andrews, Robert S Ware, Stephen B Lambert

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ashish C ShresthaQueensland Public Health and Scientific Services, Queensland Health, Brisbane, Queensland, Australia.ORCID 0000-0001-5049-8351
Emma FieldNational Centre for Epidemiology and Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.
Dharshi ThangarajahDepartment of Health and Aged Care, Canberra, Australian Capital Territory, Australia.
Ross AndrewsQueensland Public Health and Scientific Services, Queensland Health, Brisbane, Queensland, Australia.
Robert S WareGriffith Biostatistics Unit, Griffith University, Brisbane, Queensland, Australia.
Stephen B LambertQueensland Public Health and Scientific Services, Queensland Health, Brisbane, Queensland, Australia.ORCID 0000-0002-2709-193X

Funding

Australian National University Master of Philosophy (Applied Epidemiology) Scholarship
6 · The paper itself

Abstract

backgroundIn 2022, publicly funded influenza vaccine was made available to all residents of Queensland, Australia. This study compared influenza epidemiology in 2022 with previous years (2017-2021) and estimated influenza vaccine effectiveness (VE) during 2022.

methodsThe study involved a descriptive analysis of influenza notifications and a case-control study to estimate VE. Cases were notifications of laboratory-confirmed influenza, and controls were individuals who were test negative for COVID-19. Cases and controls were matched on age, postcode and specimen collection date. VE against hospitalisation was investigated by matching hospitalised cases to controls. Conditional logistic regression models were adjusted for sex.

resultsIn 2022, Queensland experienced an early influenza season onset (April-May) and high case numbers (n = 45,311), compared to the previous 5 years (annual average: 29,364) and 2020-2021 (2020:6047; 2021:301) during the COVID-19 pandemic. Adjusted VE (VE

conclusionIn Queensland, the 2022 influenza season started earlier than the previous 5 years. VE against influenza notifications varied across age groups. VE estimates against influenza-associated hospitalisation were higher than those against laboratory-confirmed influenza.

Indexed as

HospitalizationInfluenza, HumanInfluenza VaccinesVaccine EfficacyAdolescentAdultAgedAged, 80 and overCase-Control StudiesChildChild, PreschoolCOVID-19FemaleHumansInfantMaleInfluenza VaccinesAustraliafluinfluenzainfluenza vaccineQueenslandvaccine effectiveness

Identifiers

PMID39320009
PMCPMC11423337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.